Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kythera receives funding to conduct ATX-101Phase III trial
The company has started the European Phase III trials of ATX-101 in 2010 in collaboration with Intendis, Bayer HealthCare’s dermatology unit, which has licensed rights to ATX-101 outside
The company has started the European Phase III trials of ATX-101 in 2010 in collaboration with Intendis, Bayer HealthCare’s dermatology unit, which has licensed rights to ATX-101 outside
The trial aims to investigate the safety, tolerability and antiviral activity of INX-189 in conjunction with pegylated interferon and ribavirin in chronic HCV-infected genotype 2 and 3 treatment
The trial aims to evaluate the safety, tolerability and pharmacokinetics of PRC-4016 in healthy volunteers. Pronova CEO Morten Jurs said they believe PRC-4016 has an optimal profile to
The patent includes composition of the Vaxfectin adjuvant, composition of Vaxfectin-formulated vaccines, and methods for their use. Vical president and CEO Vijay Samant said Vaxfectin was discovered through
Lubrizol is a producer of ingredients and additives for personal care products and pharmaceuticals; specialty materials, as well as plastics technology and performance coatings in the form of
The randomized, placebo-controlled, double-blind study is designed to prove the concept of the use of EMA401 in PHN patients and to demonstrate its pharmacokinetic profile, tolerability, and safety.
Following the merger, the businesses were brought together under a newly-formed company, Alkermes plc, to be based in Ireland. As per the terms of the deal, Elan has
Under the agreement, both the parties have invested for combining Selcia’s medicinal and analytical chemistry, with NeuroVive’s research and development programs in mitochondrial medicine. NeuroVive CEO Mikael Bronnegard
Earlier, the company has received a warning letter from the agency on 25 August 2010 for violating good manufacturing practice regulations. The issuance of the letter follows FDA
The new deal covers several major European countries, such as Germany, France, the UK, Spain, Austria, the Netherlands and Belgium. Under the deal, Meda is responsible to pay